Viral vectors for cancer immunotherapy.

@article{Harrop2006ViralVF,
  title={Viral vectors for cancer immunotherapy.},
  author={Richard Harrop and Miles W. Carroll},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2006},
  volume={11},
  pages={
          804-17
        }
}
  • R. Harrop, M. Carroll
  • Published 2006
  • Biology
  • Frontiers in bioscience : a journal and virtual library
Over the last decade, immunotherapy approaches for the treatment of cancer have been investigated with renewed vigour, perhaps catalyzed by the clinical successes seen with monoclonal antibody and cytokine based therapies. The identification of tumor-associated antigens (TAAs) in multiple cancer types has enabled the development of targeted immunotherapies and allayed some of the safety concerns associated with the induction of deleterious autoimmune reactions. In addition to the TAA or… 
View on PubMed
bioscience.org
36 Citations
Highly Influential Citations
1
Background Citations
11
Methods Citations
1

Figures and Tables from this paper

36 Citations

Citation Type

Citation Type

Cancer Vaccines: Fundamentals and Strategies
TLDR
Targeting immunoregulatory cells and T cell inhibitory molecules with monoclonal antibodies is becoming a critical approach to enhance cancer vaccines in the clinical scenario.
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
TLDR
It is hypothesized that after viral immunogene therapy "primed" an initial strong antitumor immune response, subsequent "boosts" could be provided by sequential courses of chemotherapy, and this approach is currently being tested in a clinical trial and could be applied to other trials of viral Immunogene therapy.
Novel adenoviral vaccine encoding multiple tumor neo-antigens in combination with checkpoint blockade as a strategy for more effective cancer treatment
TLDR
A novel vaccine platform based on adenoviral vectors encoding multiple neo-antigens that have the potential to induce more robust and specific anti-cancer T cell responses than classical tumor-associated self-antIGens and tested in vivo for immunogenicity and efficacy in combination with checkpoint inhibitors.
Immunotherapeutic approaches for cancer therapy: An updated review
TLDR
The different modalities for active and passive immunotherapy for cancer are discussed, with administration of specific monoclonal antibodies against different tumor antigens and adoptive transfer of genetically-modified specific T cells being the most rapidly developing approaches for cancer targeted therapy.
Vaccine therapy for renal cancer
  • R. Amato
  • Biology, Medicine
    Expert review of vaccines
  • 2008
TLDR
Issues of tumor immunosuppression and lack of identified tumor-associated antigens must be addressed before vaccine therapy can be applied successfully in advanced renal cell cancer.
5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy
  • R. Amato
  • Biology, Medicine
    Expert opinion on biological therapy
  • 2007
TLDR
Reports from clinical trials demonstrate that MVA-5T4 is safe and highly immunogenic, both as a monotherapy and in combination with standard-of-care therapies including irinotecan, oxaliplatin, IFN-α and IL-2.
Novel immunotherapeutic strategies for gynaecologic malignancies
The main aim of the studies described in this thesis was to investigate innovative immunotherapeutic strategies for treatment of gynaecologic malignancies, in particular ovarian and cervical cancer.…
In situ adenovirus vaccination engages T effector cells against cancer.
Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
TLDR
With minimal side effects and the ability to produce a strong immunogenic response, MVA-5T4 is a viable addition to the cancer therapy arsenal.
Integrating oncolytic viruses in combination cancer immunotherapy
TLDR
Oncolytic viruses can target multiple steps in the cancer–immunity cycle and can be engineered to express therapeutic genes and, as a result, can be usefully integrated in combination cancer immunotherapies.
...
1
2
3
4
...

References

SHOWING 1-10 OF 85 REFERENCES
Modifying adenoviral vectors for use as gene-based cancer vaccines.
TLDR
The range of host responses to AdV vaccines is described, strategies to reduce viral recognition and enhance transgene antigen expression are identified, and future approaches to vector development and administration are suggested.
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
TLDR
High doses of recombinant adenoviruses could be safely administered to cancer patients and high levels of neutralizing antibody present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens.
Part I: Vaccines for solid tumours.
Poxviruses as vectors for cancer immunotherapy.
TLDR
This review focuses on recent advances in the use of poxvirus-based vaccines as cancer therapeutic agents and the strategy has been successfully documented in animal models.
Recombinant Vaccinia Virus Encoding Human MUC1 and IL2 as Immunotherapy in Patients With Breast Cancer
TLDR
The absence of serious adverse events, together with the documentation of immune stimulations in vivo, warrant the further use of TG1031 in immunotherapy trials of breast cancer.
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
TLDR
It is demonstrated that MVA, when used as a prime in a diversified vaccination, is clearly comparable with the regimen using the recombinant vaccinia in both the induction of cellular immune responses specific for the "self"-TAA transgene and in antitumor activity.
Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma
TLDR
The data underscore the importance of modifying anchor residues of nonmutated self-antigen peptides to generate cellular immune responses after immunization and support the further investigation of recombinant fowlpox viruses encoding modified epitopes administered in combination with IL-2.
Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
TLDR
It is demonstrated that incorporation of fusogenic function into an on colytic virus can significantly increase the potency of viral oncolysis; this may lead to an enhanced clinical performance, especially in late-stage cancer patients.
Transductional targeting of adenoviral cancer gene therapy.
TLDR
This review will focus on transductional targeting strategies, in which the adenoviral particle is physically targeted to specific surface receptors expressed on the target cell, using either bifunctional adaper molecules, or genetic targeting strategies.
Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer
TLDR
This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy.
...
1
2
3
4
5
...